BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

525 related articles for article (PubMed ID: 25510449)

  • 1. Expression of matrix metalloproteinases and their inhibitors in different immunohistochemical-based molecular subtypes of breast cancer.
    Kim GE; Lee JS; Choi YD; Lee KH; Lee JH; Nam JH; Choi C; Kim SS; Park MH; Yoon JH; Kweon SS
    BMC Cancer; 2014 Dec; 14():959. PubMed ID: 25510449
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prognostic Influence of Tumor Stroma on Breast Cancer Subtypes.
    Cid S; Eiro N; Fernández B; Sánchez R; Andicoechea A; Fernández-Muñiz PI; González LO; Vizoso FJ
    Clin Breast Cancer; 2018 Feb; 18(1):e123-e133. PubMed ID: 28927692
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes.
    Kim MJ; Ro JY; Ahn SH; Kim HH; Kim SB; Gong G
    Hum Pathol; 2006 Sep; 37(9):1217-26. PubMed ID: 16938528
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Expression and Clinical Significance of Metalloproteases and Their Inhibitors by Endothelial Cells From Invasive Breast Carcinomas.
    Cid S; Eiro N; González LO; Beridze N; Vazquez J; Vizoso FJ
    Clin Breast Cancer; 2016 Aug; 16(4):e83-91. PubMed ID: 27266802
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Expression and prognostic significance of fibronectin and matrix metalloproteases in breast cancer metastasis.
    Fernandez-Garcia B; Eiró N; Marín L; González-Reyes S; González LO; Lamelas ML; Vizoso FJ
    Histopathology; 2014 Mar; 64(4):512-22. PubMed ID: 24117661
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Expression of matrix metalloproteinases (MMP-2, MMP-9, MT1-MMP) and their inhibitors (TIMP-1, TIMP-2) in common epithelial tumors of the ovary.
    Sakata K; Shigemasa K; Nagai N; Ohama K
    Int J Oncol; 2000 Oct; 17(4):673-81. PubMed ID: 10995877
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Stromal matrix metalloproteinase-14 expression correlates with the grade and biological behavior of mammary phyllodes tumors.
    Kim GE; Kim JH; Lee KH; Choi YD; Lee JS; Lee JH; Nam JH; Choi C; Park MH; Yoon JH
    Appl Immunohistochem Mol Morphol; 2012 May; 20(3):298-303. PubMed ID: 22505012
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Expression and prognostic significance of metalloproteases and their inhibitors in luminal A and basal-like phenotypes of breast carcinoma.
    González LO; Corte MD; Junquera S; González-Fernández R; del Casar JM; García C; Andicoechea A; Vázquez J; Pérez-Fernández R; Vizoso FJ
    Hum Pathol; 2009 Sep; 40(9):1224-33. PubMed ID: 19439346
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [Relationship between the expression of matrix metalloproteinase-13 protein and other biomarkers, prognosis in invasive breast cancer].
    Zhang B; Liu YX; Cao WF; Cao XC; Ning LS; Hao XS
    Zhonghua Bing Li Xue Za Zhi; 2008 Jul; 37(7):471-6. PubMed ID: 19035119
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pattern of recurrence of early breast cancer is different according to intrinsic subtype and proliferation index.
    Ribelles N; Perez-Villa L; Jerez JM; Pajares B; Vicioso L; Jimenez B; de Luque V; Franco L; Gallego E; Marquez A; Alvarez M; Sanchez-Muñoz A; Perez-Rivas L; Alba E
    Breast Cancer Res; 2013; 15(5):R98. PubMed ID: 24148581
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A retrospective study of breast cancer subtypes: the risk of relapse and the relations with treatments.
    Wang Y; Yin Q; Yu Q; Zhang J; Liu Z; Wang S; Lv S; Niu Y
    Breast Cancer Res Treat; 2011 Nov; 130(2):489-98. PubMed ID: 21837481
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Identification of a basal-like subtype of breast ductal carcinoma in situ.
    Livasy CA; Perou CM; Karaca G; Cowan DW; Maia D; Jackson S; Tse CK; Nyante S; Millikan RC
    Hum Pathol; 2007 Feb; 38(2):197-204. PubMed ID: 17234468
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CORRELATION BETWEEN CLINICAL PATHOLOGY OF LUMINAL B BREAST CANCER AND DETERMINATION OF ESTROGEN RECEPTOR, PROGESTERONE RECEPTOR AND HER2 EXPRESSION COMBINED WITH NUCLEAR MORPHOLOGY.
    Yin D; Wang YL; Wang YF; Yang L; Zhang L; Tang C; Xie W; Ma Y
    J Biol Regul Homeost Agents; 2015; 29(3):579-87. PubMed ID: 26403396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes.
    Carey LA; Dees EC; Sawyer L; Gatti L; Moore DT; Collichio F; Ollila DW; Sartor CI; Graham ML; Perou CM
    Clin Cancer Res; 2007 Apr; 13(8):2329-34. PubMed ID: 17438091
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Study of matrix metalloproteinases and their inhibitors in breast cancer.
    Vizoso FJ; González LO; Corte MD; Rodríguez JC; Vázquez J; Lamelas ML; Junquera S; Merino AM; García-Muñiz JL
    Br J Cancer; 2007 Mar; 96(6):903-11. PubMed ID: 17342087
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estrogen receptor-beta expression in invasive breast cancer in relation to molecular phenotype: results from the Nurses' Health Study.
    Marotti JD; Collins LC; Hu R; Tamimi RM
    Mod Pathol; 2010 Feb; 23(2):197-204. PubMed ID: 19898422
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Study of matrix metalloproteinases and their tissue inhibitors in ductal in situ carcinomas of the breast.
    Gonzalez LO; Corte MD; Vazquez J; Junquera S; Sanchez R; Viña A; Rodriguez JC; Lamelas ML; Vizoso F
    Histopathology; 2008 Oct; 53(4):403-15. PubMed ID: 18983606
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bcl-2 is a highly significant prognostic marker of hormone-receptor-positive, human epidermal growth factor receptor-2-negative breast cancer.
    Seong MK; Lee JY; Byeon J; Sohn YJ; Seol H; Lee JK; Kim EK; Kim HA; Noh WC
    Breast Cancer Res Treat; 2015 Feb; 150(1):141-8. PubMed ID: 25682076
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic value of basal phenotype in HER2-overexpressing breast cancer.
    Bagaria SP; Ray PS; Wang J; Kropcho L; Chung A; Sim MS; Shamonki JM; Martino S; Cui X; Giuliano AE
    Ann Surg Oncol; 2012 Mar; 19(3):935-40. PubMed ID: 21879270
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Immunohistochemical identification of basal-type cytokeratins in invasive ductal breast carcinoma--relation with grade, stage, estrogen receptor and HER2.
    Kusińska R; Potemski P; Jesionek-Kupnicka D; Kordek R
    Pol J Pathol; 2005; 56(3):107-10. PubMed ID: 16334976
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.